Actinium Ac-225 Vipivotide Tetraxetan for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Jan 2025: Trial registered, NCT06780670
  2. 27 Feb 2025: Trial started, NCT06780670

The trials

NCT06780670: Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

State
Under way
Phase
Phase 2 and Phase 3
People
443 planned
Started
27 Feb 2025
Primary completion
27 Jun 2028
Arms
Phase II: AAA817 Dose B, Phase II: AAA817 Dose A, Phase III: Recommended Phase 3 Dose of AAA817
Results
None posted
  1. 17 Jan 2025: Trial registered
  2. 27 Feb 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.